Cluster Headache: managenet updates

Cluster headache (CH) is a severe primary headache disorder falling under trigeminal autonomic cephalalgia. It stands out due to its intense pain, duration of attacks, and associated cranial autonomic symptoms, occurring periodically over circadian and circannual cycles. Despite effective treatments available, delays often hinder accurate diagnosis and targeted therapy initiation. While the pathophysiology remains elusive, recent strides in understanding primary headache disorders have paved the way for newer therapeutic avenues, offering hope for non-responsive patients.

Clinical Characteristics: CH manifests as excruciating unilateral head pain lasting 15 minutes to three hours, accompanied by ipsilateral cranial autonomic symptoms like conjunctival injection, lacrimation, and nasal congestion. Attacks are typically restless and agitated.

Diagnosis: Clinical diagnosis relies on patient history and observation of cranial autonomic symptoms during an attack. Neurological examinations between attacks are typically unremarkable.

Epidemiology and Risk Factors: CH affects 0.1% of the population, with a male predilection. Onset usually occurs in the third decade, with similar clinical phenotypes in both genders.

Pathophysiology: The exact pathophysiology remains unclear. Activation of the trigeminovascular system and trigeminal-autonomic reflex, possibly through a trigeminal-hypothalamic pathway, is implicated, under the influence of fluctuating hypothalamic and central pain-processing regions.

Management: involves acute, preventive, and transitional approaches. Evidence supports parenteral triptans, high-flow oxygen for acute treatment, and verapamil for prevention. Newer therapies and neuromodulatory treatments show promise, potentially revolutionizing clinical practice.